BioAge Labs BIOA
NASDAQ BIOA
$9.17 -0.23 (-2.40%)
As of: Sep 9, 2026 · 3:59 PM EDT

BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026)

BioAge Labs' (BIOA) quarterly Income towards Parent Company came in at -$25.9 million in Q2 2026, down 20.16% year-over-year from -$32.4 million in Q2 2025, and down 16.93% quarter-over-quarter from -$22.1 million in Q1 2026.

Analysis

BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026) Analysis & Trends

BioAge Labs has disclosed Income towards Parent Company across 4 years of filings, most recently posting -$25.9 million for Q2 2026.

  • In Q2 2026, Income towards Parent Company fell 20.16% year-over-year to -$25.9 million; the TTM figure through Jun 2026 stood at -$93.9 million (down 18.51% YoY), while the FY2025 annual figure was -$80.4 million, down 13.34% from the prior year.
  • Income towards Parent Company came in at -$25.9 million for Q2 2026 at BioAge Labs, down from -$22.1 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$11.8 million in Q3 2023 to a low of -$25.9 million in Q2 2026.
  • Average Income towards Parent Company over 4 years is -$18.9 million, with a median of -$20.8 million recorded in 2025.
  • Year-over-year, Income towards Parent Company tumbled 95.92% in 2024 and climbed 12.87% in 2025.
  • Over 4 years, Income towards Parent Company stood at -$15.8 million in 2023, then tumbled by 36.83% to -$21.6 million in 2024, then decreased by 19.17% to -$25.7 million in 2025, then fell by 0.67% to -$25.9 million in 2026.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were -$25.9 million in Q2 2026, -$22.1 million in Q1 2026, and -$25.7 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 BioAge Labs 409.83 Mn 409.83 Mn -14.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -25.90 Mn
Mar 31, 2026 -22.15 Mn
Dec 31, 2025 -25.72 Mn
Sep 30, 2025 -20.13 Mn
Jun 30, 2025 -21.55 Mn
Mar 31, 2025 -12.99 Mn
Dec 31, 2024 -21.59 Mn
Sep 30, 2024 -23.10 Mn
Jun 30, 2024 -13.51 Mn
Mar 31, 2024 -12.73 Mn
Dec 31, 2023 -15.78 Mn
Sep 30, 2023 -11.79 Mn